Deep patent portfolios help drugmakers block market entry by potential biosimilars, but many biologic patents logically cannot be valid barriers to competitive entry.
CITATION STYLE
Price, W. N., & Rai, A. K. (2019). How logically impossible patents block biosimilars. Nature Biotechnology, 37(8), 862–863. https://doi.org/10.1038/s41587-019-0196-x
Mendeley helps you to discover research relevant for your work.